AMN Healthcare Services (AMN)
(Delayed Data from NYSE)
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.57 USD
-0.06 (-0.14%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $42.57 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Strong performance across the Diabetes Care and EPD businesses is driving the top line for Abbott (ABT).
QIAGEN (QGEN) to Acquire Poland-Based Enzymes Manufacturer
by Zacks Equity Research
The latest acquisition of BLIRT will allow QIAGEN (QGEN) to tap into the high opportunities within the life science industry.
Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio For Now
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Doximity (DOCS) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Doximity's (DOCS) fiscal fourth-quarter results are likely to reflect continued strength in its telehealth platform.
BD (BDX) Extends Partnership to Boost Diagnostic Blood Collection
by Zacks Equity Research
BD (BDX) expands strategic partnership with Babson Diagnostics that will enable less invasive blood sample collection easier and patient-centric.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Here's Why Investors Should Retain Medtronic (MDT) Stock
by Zacks Equity Research
Investors are optimistic about Medtronic's (MDT) rising market share gains and ongoing business recovery.
Here's Why You Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) better-than-expected earnings and robust segmental performance.
Inogen (INGN) Stock Inches Up 0.5% Post Q1 Earnings Beat
by Zacks Equity Research
Inogen's (INGN) first-quarter results benefit from higher revenues across the majority of its geographical segments and categories.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vince Surgical System. Higher production costs are a woe.
3 Reasons Why AMN Healthcare (AMN) Is a Great Growth Stock
by Zacks Equity Research
AMN Healthcare (AMN) possesses solid growth attributes, which could help it handily outperform the market.
OPKO Health (OPK) Post In-Line Q1 Earnings, Revenues Top
by Zacks Equity Research
OPKO Health's (OPK) first-quarter results benefit from continued strength in its Pharmaceuticals segment.
Here's Why You Should Hold on to CVS Health (CVS) For Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) better-than-expected results and strong retail sales.
Best Growth Stocks to Buy for May 10th
by Zacks Equity Research
AMN, GEO, and AA made it to the Zacks Rank #1 (Strong Buy) growth stocks list on May 10, 2022.
AMN vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
AMN Healthcare (AMN) Q1 Earnings, Revenues Beat Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q1 results demonstrate its segmental strength.
AMN Healthcare Services (AMN) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 7.38% and 3.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Here's Why You Should Hold on to Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) given the strong demand for its RESILIA tissue valves and the PASCAL system.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in base business and raised 2022 outlook.
AMN Healthcare (AMN) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
AMN Healthcare's (AMN) first-quarter results are likely to reflect solid demand in some of the areas of its business.
AMN Healthcare Services (AMN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AMN Healthcare Services (AMN) closed at $103.49, marking a -1.14% move from the previous day.
Here's Why You Should Retain Allscripts (MDRX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Allscripts Healthcare Solutions (MDRX) owing to its strategic alliances.
AMN vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
Here's Why You Should Retain Integra (IART) Stock For Now
by Zacks Equity Research
Investors are optimistic about Integra (IART), given the strength in its CSS arm and notable product launches.